Multimorbidity and use of hypnotic and anxiolytic drugs: cross-sectional and follow-up study in primary healthcare in Iceland
Abstract Background The prevalence of multimorbidity is increasing worldwide, presumably leading to an increased use of medicines. During the last decades the use of hypnotic and anxiolytic benzodiazepine derivatives and related drugs has increased dramatically. These drugs are frequently prescribed...
Main Authors: | , , , , , , |
---|---|
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
BioMed Central Ltd.
2016
|
Subjects: | |
Online Access: | http://www.biomedcentral.com/1471-2296/17/69 |
id |
ftbiomed:oai:biomedcentral.com:s12875-016-0469-0 |
---|---|
record_format |
openpolar |
spelling |
ftbiomed:oai:biomedcentral.com:s12875-016-0469-0 2023-05-15T16:48:19+02:00 Multimorbidity and use of hypnotic and anxiolytic drugs: cross-sectional and follow-up study in primary healthcare in Iceland Linnet, Kristjan Gudmundsson, Larus Birgisdottir, Frida Sigurdsson, Emil Johannsson, Magnus Tomasdottir, Margret Sigurdsson, Johann 2016-06-06 http://www.biomedcentral.com/1471-2296/17/69 en eng BioMed Central Ltd. http://www.biomedcentral.com/1471-2296/17/69 Copyright 2016 The Author(s). Hypnotics Anxiolytics Multimorbidity ICD-10 Primary care Chronic health problems Multiple chronic conditions Insomnia Research article 2016 ftbiomed 2016-06-12T00:00:09Z Abstract Background The prevalence of multimorbidity is increasing worldwide, presumably leading to an increased use of medicines. During the last decades the use of hypnotic and anxiolytic benzodiazepine derivatives and related drugs has increased dramatically. These drugs are frequently prescribed for people with a sleep disorder often merely designated as “insomnia” in the medical records and lacking a clear connection with the roots of the patients’ problems. Our aim was to analyse the prevalence of multimorbidity in primary healthcare in Iceland, while concurrently investigating a possible association with the prevalence and incidence of hypnotic/anxiolytic prescriptions, short-term versus chronic use. Methods Data were retrieved from a comprehensive database of medical records from primary healthcare in Iceland to find multimorbid patients and prescriptions for hypnotics and anxiolytics, linking diagnoses (ICD-10) and prescriptions (2009–2012) to examine a possible association. Nearly 222,000 patients, 83 % being local residents in the capital area, who contacted 16 healthcare centres served in total by 140 general practitioners, were set as a reference to find the prevalence of multimorbidity as well as the prevalence and incidence of hypnotic/anxiolytic prescriptions. Results The prevalence of multimorbidity in the primary care population was 35 %, lowest in the young, increasing with age up to the 80+ group where it dropped somewhat. The prevalence of hypnotic/anxiolytic prescriptions was 13.9 %. The incidence rate was 19.4 per 1000 persons per year in 2011, and 85 % of the patients prescribed hypnotics/anxiolytics were multimorbid. Compared to patients without multimorbidity, multimorbid patients were far more likely to be prescribed a hypnotic and/or an anxiolytic, OR = 14.9 (95 % CI = 14.4–15.4). Conclusions Patients with multiple chronic conditions are common in the primary care setting, and prevalence and incidence of hypnotic/anxiolytic prescriptions are high. Solely explaining use of these drugs by linear thinking, i.e. that “insomnia” leads to their prescription is probably simplistic, since the majority of patients prescribed these drugs are multimorbid having several chronic conditions which could lead to sleeping problems. However, multimorbidity as such is not an indication for hypnotics, and doctors should be urged to . Article in Journal/Newspaper Iceland BioMed Central |
institution |
Open Polar |
collection |
BioMed Central |
op_collection_id |
ftbiomed |
language |
English |
topic |
Hypnotics Anxiolytics Multimorbidity ICD-10 Primary care Chronic health problems Multiple chronic conditions Insomnia |
spellingShingle |
Hypnotics Anxiolytics Multimorbidity ICD-10 Primary care Chronic health problems Multiple chronic conditions Insomnia Linnet, Kristjan Gudmundsson, Larus Birgisdottir, Frida Sigurdsson, Emil Johannsson, Magnus Tomasdottir, Margret Sigurdsson, Johann Multimorbidity and use of hypnotic and anxiolytic drugs: cross-sectional and follow-up study in primary healthcare in Iceland |
topic_facet |
Hypnotics Anxiolytics Multimorbidity ICD-10 Primary care Chronic health problems Multiple chronic conditions Insomnia |
description |
Abstract Background The prevalence of multimorbidity is increasing worldwide, presumably leading to an increased use of medicines. During the last decades the use of hypnotic and anxiolytic benzodiazepine derivatives and related drugs has increased dramatically. These drugs are frequently prescribed for people with a sleep disorder often merely designated as “insomnia” in the medical records and lacking a clear connection with the roots of the patients’ problems. Our aim was to analyse the prevalence of multimorbidity in primary healthcare in Iceland, while concurrently investigating a possible association with the prevalence and incidence of hypnotic/anxiolytic prescriptions, short-term versus chronic use. Methods Data were retrieved from a comprehensive database of medical records from primary healthcare in Iceland to find multimorbid patients and prescriptions for hypnotics and anxiolytics, linking diagnoses (ICD-10) and prescriptions (2009–2012) to examine a possible association. Nearly 222,000 patients, 83 % being local residents in the capital area, who contacted 16 healthcare centres served in total by 140 general practitioners, were set as a reference to find the prevalence of multimorbidity as well as the prevalence and incidence of hypnotic/anxiolytic prescriptions. Results The prevalence of multimorbidity in the primary care population was 35 %, lowest in the young, increasing with age up to the 80+ group where it dropped somewhat. The prevalence of hypnotic/anxiolytic prescriptions was 13.9 %. The incidence rate was 19.4 per 1000 persons per year in 2011, and 85 % of the patients prescribed hypnotics/anxiolytics were multimorbid. Compared to patients without multimorbidity, multimorbid patients were far more likely to be prescribed a hypnotic and/or an anxiolytic, OR = 14.9 (95 % CI = 14.4–15.4). Conclusions Patients with multiple chronic conditions are common in the primary care setting, and prevalence and incidence of hypnotic/anxiolytic prescriptions are high. Solely explaining use of these drugs by linear thinking, i.e. that “insomnia” leads to their prescription is probably simplistic, since the majority of patients prescribed these drugs are multimorbid having several chronic conditions which could lead to sleeping problems. However, multimorbidity as such is not an indication for hypnotics, and doctors should be urged to . |
format |
Article in Journal/Newspaper |
author |
Linnet, Kristjan Gudmundsson, Larus Birgisdottir, Frida Sigurdsson, Emil Johannsson, Magnus Tomasdottir, Margret Sigurdsson, Johann |
author_facet |
Linnet, Kristjan Gudmundsson, Larus Birgisdottir, Frida Sigurdsson, Emil Johannsson, Magnus Tomasdottir, Margret Sigurdsson, Johann |
author_sort |
Linnet, Kristjan |
title |
Multimorbidity and use of hypnotic and anxiolytic drugs: cross-sectional and follow-up study in primary healthcare in Iceland |
title_short |
Multimorbidity and use of hypnotic and anxiolytic drugs: cross-sectional and follow-up study in primary healthcare in Iceland |
title_full |
Multimorbidity and use of hypnotic and anxiolytic drugs: cross-sectional and follow-up study in primary healthcare in Iceland |
title_fullStr |
Multimorbidity and use of hypnotic and anxiolytic drugs: cross-sectional and follow-up study in primary healthcare in Iceland |
title_full_unstemmed |
Multimorbidity and use of hypnotic and anxiolytic drugs: cross-sectional and follow-up study in primary healthcare in Iceland |
title_sort |
multimorbidity and use of hypnotic and anxiolytic drugs: cross-sectional and follow-up study in primary healthcare in iceland |
publisher |
BioMed Central Ltd. |
publishDate |
2016 |
url |
http://www.biomedcentral.com/1471-2296/17/69 |
genre |
Iceland |
genre_facet |
Iceland |
op_relation |
http://www.biomedcentral.com/1471-2296/17/69 |
op_rights |
Copyright 2016 The Author(s). |
_version_ |
1766038421775581184 |